Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Why the future of marijuana legalization remains hazy despite high public support 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Moderna to Pay Up to $2.25B to Settle LNP Patent Dispute Over COVID-19 Vaccine Technology 
China Car Sales Drop Again as EV Export Growth Surges in April 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
Norway Core Inflation Hits 3.2% in April, Fueling Interest Rate Hike Expectations 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
Trump-Xi China Summit 2026: Trade Tensions, Taiwan, and Iran Take Center Stage 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
